Comment from Amneal Pharmaceuticals LLC

Summary: Amneal Pharmaceuticals LLC supports the FDA's information solicitation regarding SUPAC guidances and recommends updating them to reflect modern manufacturing technologies and risk-based principles. The company argues for consolidating the guidances, harmonizing terminology with other FDA regulations, and incorporating more flexible, science-driven approaches for various dosage forms and complex generics.